3-iodobenzylguanidine has been researched along with Neuroendocrine Tumors in 100 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (14.00) | 18.2507 |
| 2000's | 42 (42.00) | 29.6817 |
| 2010's | 36 (36.00) | 24.3611 |
| 2020's | 8 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Flux, G; Gape, P; Gear, J; Leek, F; Taprogge, J | 1 |
| He, H; Xu, Q; Yu, C | 1 |
| Jimenez, C; Lu, Y; Xu, G | 1 |
| Cicone, F; Cremonesi, M; Gabiña, PM; Gear, J; Giovanella, L; Gnesin, S; Herrmann, K; Hustinx, R; Sandström, M; Stokke, C; Terwinghe, C; Tran-Gia, J; Verburg, F | 1 |
| Abid, K; Beck Popovic, M; Eugster, PJ; Fani, M; Gaonkar, RH; Grand-Guillaume, J; Grouzmann, E; Mansi, R; Zanger, S | 1 |
| Bal, CS; Dadhwal, R; Jain, S; Seth, A | 1 |
| Jimenez, C; Núñez, R; Wendt, R | 1 |
| Besenyi, Z; Farkas, I; Pávics, L; Sipka, G | 1 |
| Rowe, SP; Sadaghiani, MS; Sheikhbahaei, S; Solnes, LB | 1 |
| Galbavy, S; Kokavec, M; Svec, A; Zamborsky, R | 1 |
| Divgi, C | 1 |
| Balogova, S; Huchet, V; Kerrou, K; Michaud, L; Montravers, F; Nataf, V; Talbot, JN | 1 |
| Akker, SA; Amendra, D; Drake, WM; Druce, MR; Goddard, I; Grossman, AB; Plowman, PN; Shieh, SC; Sze, WC | 1 |
| Pápai, Z; Uhlyarik, A | 1 |
| Bergestuen, DS; Khan, MS; Kim, MK; Oberg, K; Rinke, A; Salazar, R; Thirlwell, C; Toumpanakis, C | 1 |
| Bombardieri, E; Chiti, A; Lorenzoni, A; Pepe, G | 1 |
| Glaudemans, AW; Koopmans, KP | 1 |
| Buteau, FA; Makis, W; McCann, K; McEwan, AJ | 1 |
| Makis, W; McCann, K; McEwan, AJ | 2 |
| Higuchi, T; Jinguji, M; Kawamoto, H; Kinuya, S; Kurihara, H; Yoshinaga, K | 2 |
| Delgado, A; Flux, G; Fombellida, JC; Genollá, J; Guayambuco, S; Mínguez, P; Sjögreen Gleisner, K | 1 |
| Chakravartty, R; Corcoran, B; Devlin, L; Kalogianni, E; Mulholland, N; Vivian, G | 1 |
| Besenyi, Z; Pávics, L | 1 |
| Bryanton, M; Makis, W; McCann, K; McEwan, AJ | 1 |
| Makis, W; McEwan, AJ; Morrish, D; Rahimi, B; Riauka, TA | 1 |
| Boyd, M; Mairs, RJ | 2 |
| Rufini, V; Shulkin, B | 1 |
| Kinuya, S; Nakajo, M; Oriuchi, N; Yamaguchi, T; Yokoyama, K; Yoshinaga, K | 1 |
| Kotzerke, J; Popp, M; Stroszczynski, C; Strumpf, A; Zöphel, K | 2 |
| Bombardieri, E; Lucignani, G | 1 |
| McEwan, AJ; Postema, EJ | 1 |
| Alhashimi, DM; Buscombe, JR; Caplin, ME; Navalkissoor, S; Quigley, AM | 1 |
| Ezziddin, S; Grünwald, F | 1 |
| Binderup, T; Federspiel, B; Hansen, CP; Højgaard, L; Kjaer, A; Knigge, U; Loft, A; Mortensen, J; Pfeifer, A | 1 |
| Baum, RP; Howman-Giles, R; Schmidt, M; Simon, T | 1 |
| Hicks, RJ | 1 |
| Mathur, A; Prabhakar, G; Sachdev, SS; Shunmugam, G; Sivaprasad, N; Teje, YD | 1 |
| Anthony, LB; Boudreaux, JP; Campeau, R; Cundiff, J; Go, VL; Joseph, S; O'Dorisio, T; Raines, D; Vinik, AI; Wang, YZ; Woltering, EA | 1 |
| Bardiès, M; Buvat, I | 1 |
| Chittenden, SJ; Flux, GD; Gaze, MN; Saran, F | 1 |
| Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ; Valkema, R | 1 |
| Bomanji, JB; Papathanasiou, ND | 1 |
| Bal, CS; Naswa, N | 1 |
| Corssmit, EP; Smit, JW; Stokkel, MP; van der Hiel, B; van Hulsteijn, LT | 1 |
| Buscombe, J; Gnanasegaran, G; Lu, SJ; Navalkissoor, S | 1 |
| Akahane, M; Ijichi, H; Inoue, Y; Kitazawa, T; Obi, S; Ohtomo, K; Omata, M; Yoshikawa, K | 1 |
| Barthel, B; Beck, NI; Höpfner, M; Jockers-Scherübl, MC; Maaser, K; Scherübl, H; Sutter, AP; Zeitz, M | 1 |
| Bacher, K; Brans, B; Dierckx, R; Monsieurs, M; Thierens, H | 1 |
| Berner, U; Diehl, M; Döbert, N; Graichen, S; Grünwald, F; Hamscho, N; Menzel, C; Risse, JH | 1 |
| Bomanji, JB; Cassoni, A; Ell, PJ; Gaze, MN; Solano, J; Waddington, W; Wong, W | 1 |
| Kobayashi, K; Kubota, T; Nakai, T; Nishimura, T; Okuyama, C; Ushijima, Y; Yoshida, T | 1 |
| Ahlman, H; Bernhardt, P; Forssell-Aronsson, E; Johanson, V; Kölby, L; Levin-Jakobsen, AM; Nilsson, O; Wängberg, B | 1 |
| Lewington, VJ | 1 |
| Aktolun, C; Baum, RP; Bishof-Delaloye, A; Bombardieri, E; Buscombe, J; Chatal, JF; Maffioli, L; Moncayo, R; Mortelmans, L; Reske, SN | 1 |
| Ahlman, H; Bernhardt, P; Forssell-Aronsson, E; Jakobsen, AM; Kölby, L; Nilsson, O | 1 |
| Ahnert-Hilger, G; Höpfner, M; Huether, A; Scherübl, H; Sutter, AP | 1 |
| Buxton-Thomas, M; Jarosz, J; Portmann, B; Riordan-Eva, P; Sivagnanavel, V | 1 |
| Aparicio, T; Askienazy, S; de Labriolle-Vaylet, C; Faraggi, M; Giraudet, AL; Mignon, M; Nguyen, C; Rouzet, F; Sobhani, I | 1 |
| McEwan, AJ; Pasieka, JL; Rorstad, O | 1 |
| Buscombe, JR; Caplin, ME; Cwikla, JB; Hilson, AJ | 1 |
| Bredow, J; Brogsitter, C; Kittner, T; Kotzerke, J; Pinkert, J | 1 |
| Ahmadzadehfar, H; Biersack, HJ; Bucerius, J; Ezziddin, S; Fischer, HP; Logvinski, T; Palmedo, H; Reinhardt, MJ; Yong-Hing, C | 1 |
| Besse, IM; Bushnell, DL; Juweid, ME; Madsen, MT; Menda, Y; O'Dorisio, MS; O'Dorisio, T | 1 |
| Buscombe, JR; Caplin, ME; Gnanasegaran, G; Hilson, AJ; Quigley, AM; Roberts, D; Shah, T | 1 |
| Baum, RP; Calcagni, ML; Rufini, V | 1 |
| Bodei, L; Brans, B; Giammarile, F; Linden, O; Luster, M; Oyen, WJG; Tennvall, J | 1 |
| Garske, U; Orlefors, H; Sundin, A | 1 |
| Bardies, M; Chiesa, C; Flux, G; Lassmann, M; Monsieurs, M; Savolainen, S; Strand, SE | 1 |
| Hirata, K; Inoue, T; Kanegae, K; Morita, K; Okamoto, S; Shiga, T; Tamaki, N; Yoshinaga, K | 1 |
| Alexakis, N; Neoptolemos, JP | 1 |
| Jones, L; Nwosu, AC; Poston, GJ; Pritchard, DM; Vinjamuri, S; Vora, J | 1 |
| Kvols, LK; Wiseman, GA | 1 |
| Hoefnagel, CA | 2 |
| Coutris, G; Mensch, B; Montravers, F; Sarda, L; Talbot, JN | 1 |
| Buxton-Thomas, M; Ramage, JK; Williams, R | 1 |
| Shapiro, B | 2 |
| Gross, MD; Shapiro, B; Shulkin, BL; Sisson, JC; Zempel, S | 1 |
| Han, R; Mitrovic, S; Zagar, I | 1 |
| Acampa, W; Bernardy, JD; Klain, M; Lastoria, S; Maurea, S; Muto, P; Salvatore, M; Varrella, P; Vergara, E | 1 |
| Critchley, M | 1 |
| Dwamena, BA; Klopper, JF; Shapiro, B; Van Heerden, B; Wieland, D; Zempel, S | 1 |
| Askienazy, S; de Labriolle-Vaylet, C; Lebtahi, R; Mure, A | 1 |
| Bukowski, RM; Pelley, RJ | 1 |
| Bombardieri, E; Castellani, MR; Chiti, A; Seregni, E | 1 |
| Chatal, JF; Kraeber-Bodéré, F; Le Bodic, MF; Resche, I; Rousseau, C | 1 |
| Besser, GM; Britton, KE; Chew, SL; Foley, R; Grossman, AB; Heintz, E; Jenkins, PJ; Kaltsas, G; Korbonits, M; Monson, JP; Mukherjee, JJ; Reznek, R | 1 |
| Arnáiz, F; Castell, M; La Banda, JP; Secades, I; Torres, M | 1 |
| Bomanji, JB; Costa, DC; Ell, PJ; Le Rest, C; Townsend, CE; Visvikis, D | 1 |
| Bettman, L; Engel, A; Even-Sapir, E; Gaitini, D; Guralnik, L; Iosilevsky, G; Israel, O; Keidar, Z; Sachs, J; Werbin, N | 1 |
| Besser, GM; Britton, KE; Chew, SL; Foley, R; Grossman, AB; Hikmat, J; Islam, N; Jenkins, PJ; Kaltsas, GA; Monson, JP; Mukherjee, JJ; Plowman, PN | 1 |
| Bombardieri, E; Chiti, A; De Deckere, E; Maccauro, M; Savelli, G | 1 |
| Grossman, AB; Kaltsas, GA; Mukherjee, JJ | 1 |
| Brans, B; Dierckx, RA; Kaufman, JM; Laureys, G; Monsieurs, M; Thierens, H | 1 |
| Grossman, AB; Kaltsas, G; Mukherjee, JJ; Plowman, PN | 1 |
44 review(s) available for 3-iodobenzylguanidine and Neuroendocrine Tumors
| Article | Year |
|---|---|
Iodine-131 and Iodine-131-Meta-iodobenzylguanidine Dosimetry in Cancer Therapy.
Topics: 3-Iodobenzylguanidine; Adult; Child; Humans; Iodine Radioisotopes; Multicenter Studies as Topic; Neuroendocrine Tumors; Radiometry; Radiotherapy Dosage; Thyroid Neoplasms | 2022 |
The efficacy and safety of Iodine-131-metaiodobenzylguanidine therapy in patients with neuroblastoma: a meta-analysis.
Topics: 3-Iodobenzylguanidine; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Female; Humans; Infant; Iodine Radioisotopes; Male; Neuroblastoma; Neuroendocrine Tumors; Neutropenia; Survival Rate; Treatment Outcome | 2022 |
High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Carcinoma, Neuroendocrine; Humans; Intestinal Neoplasms; Iodine Radioisotopes; Neoplasm Metastasis; Neuroblastoma; Neuroendocrine Tumors; Pancreatic Neoplasms; Paraganglioma; Pheochromocytoma; Rare Diseases; Stomach Neoplasms; Therapies, Investigational; Thyroid Neoplasms | 2020 |
Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice.
Topics: 3-Iodobenzylguanidine; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pheochromocytoma; Precision Medicine; Radiopharmaceuticals | 2021 |
Bone metastases in neuroendocrine tumors.
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Chromogranin A; Diphosphonates; Fractures, Spontaneous; Humans; Hypercalcemia; Neuroendocrine Tumors; Radiotherapy; Somatostatin; Spinal Cord Compression; Surgical Procedures, Operative | 2017 |
18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
Topics: 3-Iodobenzylguanidine; Bronchial Neoplasms; Carcinoma, Merkel Cell; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Lung Neoplasms; Multimodal Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Recurrence; Sensitivity and Specificity; Thyroid Neoplasms; Tomography, Emission-Computed, Single-Photon | 2013 |
[Diagnosis and treatment options of neuroendocrine tumours].
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Chromogranin A; Diagnosis, Differential; Diagnostic Imaging; Humans; Neuroendocrine Tumors; Prognosis; Radiotherapy, Adjuvant; Receptors, Peptide | 2013 |
Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors.
Topics: 3-Iodobenzylguanidine; Digestive System Neoplasms; Fluorodeoxyglucose F18; Humans; Intestinal Neoplasms; Magnetic Resonance Imaging; Molecular Imaging; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Radionuclide Imaging; Receptors, Somatostatin; Sensitivity and Specificity; Stomach Neoplasms; Surveys and Questionnaires; Tomography, X-Ray Computed; Ultrasonography | 2014 |
Single-photon emission computed tomography tracers in the diagnostics of neuroendocrine tumors.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Carcinoma, Neuroendocrine; Contraindications; Humans; Intestinal Neoplasms; Lung Neoplasms; Neuroblastoma; Neuroendocrine Tumors; Pancreatic Neoplasms; Paraganglioma; Pheochromocytoma; Pituitary Neoplasms; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Stomach Neoplasms; Thyroid Neoplasms; Tomography, Emission-Computed, Single-Photon | 2014 |
Other PET tracers for neuroendocrine tumors.
Topics: 3-Iodobenzylguanidine; 5-Hydroxytryptophan; Carbon Radioisotopes; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Stomach Neoplasms | 2014 |
[Nuclear medicine in oncotherapy].
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Bone Neoplasms; Humans; Interdisciplinary Communication; Iodine Radioisotopes; Liver Neoplasms; Medical Oncology; Neuroendocrine Tumors; Nuclear Medicine; Prevalence; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Radium; Receptors, Somatostatin; Thyroid Neoplasms | 2015 |
Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy.
Topics: 3-Iodobenzylguanidine; Bystander Effect; Combined Modality Therapy; Humans; Neuroendocrine Tumors; Radiopharmaceuticals; Radiotherapy Dosage; Topotecan | 2008 |
The evolution in the use of MIBG in more than 25 years of experimental and clinical applications.
Topics: 3-Iodobenzylguanidine; Animals; Humans; Literature; Neuroendocrine Tumors; Radiochemistry; Tissue Distribution | 2008 |
Progress and challenges in neuroendocrine and neural crest tumours: molecular imaging and therapy.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Animals; Disease Progression; Humans; Molecular Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Radionuclide Imaging | 2009 |
Radioiodinated metaiodobenzylguanidine treatment of neuroendocrine tumors in adults.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Algorithms; Carcinoid Tumor; Carcinoma, Medullary; Drug Interactions; Humans; Iodine Radioisotopes; Male; Medical Oncology; Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma; Radiopharmaceuticals; Thyroid Neoplasms | 2009 |
131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors.
Topics: 3-Iodobenzylguanidine; Animals; Combined Modality Therapy; Humans; Neuroblastoma; Neuroendocrine Tumors | 2010 |
Therapeutic nuclear medicine in pediatric malignancy.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Combined Modality Therapy; Humans; Iodine Radioisotopes; Neoplasms; Neuroblastoma; Neuroendocrine Tumors; Osteosarcoma; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Receptors, Somatostatin; Thyroid Neoplasms | 2010 |
Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.
Topics: 3-Iodobenzylguanidine; Humans; Neoplasm Staging; Neuroendocrine Tumors; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2010 |
Neuroendocrine tumors: current recommendations for diagnosis and surgical management.
Topics: 3-Iodobenzylguanidine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoembolization, Therapeutic; Combined Modality Therapy; Gastrointestinal Neoplasms; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Pancreatic Neoplasms; Practice Guidelines as Topic; Radionuclide Imaging; Somatostatin | 2011 |
Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry?
Topics: 3-Iodobenzylguanidine; Bone Marrow; Carcinoma, Hepatocellular; Humans; Iodine Radioisotopes; Liver Neoplasms; Lymphoma, Non-Hodgkin; Neoplasms; Neuroendocrine Tumors; Nuclear Medicine; Radioimmunotherapy; Radiopharmaceuticals; Radiotherapy; Radiotherapy Planning, Computer-Assisted; Thyroid Neoplasms; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2011 |
Clinical applications of dosimetry for mIBG therapy.
Topics: 3-Iodobenzylguanidine; Adult; Child; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted | 2011 |
Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors.
Topics: 3-Iodobenzylguanidine; Animals; Bystander Effect; Cell Line, Tumor; Drug Interactions; Enzyme Inhibitors; Humans; Neuroendocrine Tumors | 2011 |
Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Gastrointestinal Neoplasms; Humans; Ligands; Magnetic Resonance Imaging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radioisotopes; Radionuclide Imaging; Receptors, Somatostatin; Tomography, X-Ray Computed | 2011 |
¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.
Topics: 3-Iodobenzylguanidine; Carcinoid Tumor; Carcinoma, Neuroendocrine; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Octreotide; Paraganglioma; Pentetic Acid; Pheochromocytoma; Radiopharmaceuticals; Receptors, Somatostatin; Thyroid Neoplasms | 2012 |
Divergent role of (68)Ga-labeled somatostatin analogs in the workup of patients with NETs: AIIMS experience.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Gallium Radioisotopes; Gastrointestinal Neoplasms; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Pheochromocytoma; Radionuclide Imaging; Radiopharmaceuticals; Somatostatin | 2013 |
Is there a role for radioguided surgery with iodine-labeled metaiodobenzylguanidine in resection of neuroendocrine tumors?
Topics: 3-Iodobenzylguanidine; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Radionuclide Imaging; Radiosurgery; Staining and Labeling | 2012 |
Single photon emission computed tomography/computed tomography in the evaluation of neuroendocrine tumours: a review of the literature.
Topics: 3-Iodobenzylguanidine; Humans; Iodine Radioisotopes; Multimodal Imaging; Neuroendocrine Tumors; Positron-Emission Tomography; Somatostatin; Tomography, X-Ray Computed | 2013 |
Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Iodine Radioisotopes; Male; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Survival Rate; Treatment Outcome | 2003 |
Targeted radionuclide therapy for neuroendocrine tumours.
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Peptides, Cyclic; Radiopharmaceuticals; Somatostatin; Yttrium Radioisotopes | 2003 |
Imaging of neuroendocrine tumors.
Topics: 3-Iodobenzylguanidine; ACTH Syndrome, Ectopic; Adrenal Gland Neoplasms; Adult; Carcinoma, Medullary; Catecholamines; Child; Gastrointestinal Neoplasms; Humans; Iodine Radioisotopes; Middle Aged; Neuroblastoma; Neuroendocrine Tumors; Octreotide; Paraganglioma; Pheochromocytoma; Positron-Emission Tomography; Radiopharmaceuticals; Somatostatin; Thyroid Neoplasms | 2006 |
Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".
Topics: 3-Iodobenzylguanidine; Animals; Clinical Trials as Topic; Dose-Response Relationship, Radiation; Humans; Iodine Radioisotopes; Lymphoma; Maximum Tolerated Dose; Neuroendocrine Tumors; Peptides; Radioimmunotherapy; Radiometry; Radiotherapy; Thyroid Neoplasms | 2007 |
Nuclear imaging of neuroendocrine tumours.
Topics: 3-Iodobenzylguanidine; 5-Hydroxytryptophan; Carbidopa; Glucose-6-Phosphate; Humans; Levodopa; Neuroendocrine Tumors; Positron-Emission Tomography; Receptors, Somatostatin; Somatostatin | 2007 |
Pancreatic neuroendocrine tumours.
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Hormones; Humans; Liver Neoplasms; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Receptors, Somatostatin; Somatostatin; Tomography, X-Ray Computed; von Hippel-Lindau Disease | 2008 |
Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues.
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Humans; Indium Radioisotopes; Iodine Radioisotopes; Iodobenzenes; Neuroendocrine Tumors; Somatostatin | 1995 |
Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours.
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Humans; Indium Radioisotopes; Iodine Radioisotopes; Iodobenzenes; Neural Crest; Neuroectodermal Tumors; Neuroendocrine Tumors; Radionuclide Imaging; Somatostatin | 1994 |
Radiopharmaceutical diagnosis and therapy of sympatho-medullary disorders.
Topics: 3-Iodobenzylguanidine; Apudoma; Humans; Iodine Radioisotopes; Iodobenzenes; Neuroblastoma; Neuroendocrine Tumors; Pheochromocytoma | 1996 |
The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Carcinoid Tumor; Carcinoma, Medullary; Heart; Hormone Antagonists; Humans; Iodine Radioisotopes; Iodobenzenes; Neuroblastoma; Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma; Radiology, Interventional; Radiopharmaceuticals; Sensitivity and Specificity; Somatostatin; Sympathetic Nervous System; Thyroid Neoplasms; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1995 |
Octreotide scanning for carcinoid tumours.
Topics: 3-Iodobenzylguanidine; Animals; Antineoplastic Agents, Hormonal; Carcinoid Tumor; Humans; Indium Radioisotopes; Iodine Radioisotopes; Neuroendocrine Tumors; Octreotide; Tomography, Emission-Computed, Single-Photon | 1997 |
[Imaging of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors].
Topics: 3-Iodobenzylguanidine; Amino Acid Sequence; Gastrointestinal Neoplasms; Humans; Intraoperative Care; Molecular Sequence Data; Neuroendocrine Tumors; Pancreatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin | 1998 |
Recent advances in systemic therapy for gastrointestinal neuroendocrine tumors.
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Gastrointestinal Neoplasms; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Somatostatin | 1999 |
Nuclear medicine applications for neuroendocrine tumors.
Topics: 3-Iodobenzylguanidine; Carcinoid Tumor; Female; Humans; Male; Neuroendocrine Tumors; Nuclear Medicine; Octreotide; Pheochromocytoma; Prognosis; Radioimmunotherapy; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Thyroid Neoplasms | 2000 |
Nuclear medicine imaging of neuroendocrine tumours.
Topics: 3-Iodobenzylguanidine; 5-Hydroxytryptophan; Antibodies, Monoclonal; Fluorodeoxyglucose F18; Humans; Iodine Radioisotopes; Levodopa; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiopharmaceuticals; Somatostatin; Tomography, Emission-Computed | 2001 |
The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
Topics: 3-Iodobenzylguanidine; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Octreotide; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Somatostatin; Yttrium Radioisotopes | 2001 |
The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours.
Topics: 3-Iodobenzylguanidine; Humans; Interferon-alpha; Iodine Radioisotopes; Neuroendocrine Tumors; Quality of Life; Somatostatin | 2001 |
2 trial(s) available for 3-iodobenzylguanidine and Neuroendocrine Tumors
| Article | Year |
|---|---|
Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans.
Topics: 3-Iodobenzylguanidine; Adolescent; Adult; Aged; Body Burden; Child; Child, Preschool; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuroendocrine Tumors; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Whole-Body Counting | 2002 |
Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiopharmaceuticals; Salvage Therapy; Somatostatin; Survival Analysis; Terminal Care; Treatment Failure; Treatment Outcome | 2004 |
54 other study(ies) available for 3-iodobenzylguanidine and Neuroendocrine Tumors
| Article | Year |
|---|---|
Proposed MIBG Scan-Based Tumor Response Criteria of High-Specific-Activity 131 I-MIBG Therapy in Metastatic Pheochromocytoma/Paraganglioma.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Brain Neoplasms; Humans; Neoplasms, Second Primary; Neuroendocrine Tumors; Paraganglioma; Peripheral Nervous System Neoplasms; Pheochromocytoma | 2023 |
EANM enabling guide: how to improve the accessibility of clinical dosimetry.
Topics: 3-Iodobenzylguanidine; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Radiometry | 2023 |
CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (
Topics: 3-Iodobenzylguanidine; Animals; Histone Deacetylase Inhibitors; Humans; Mice; Neuroblastoma; Neuroendocrine Tumors; Phosphatidylinositol 3-Kinases; Precision Medicine | 2023 |
Neuroendocrine tumour of urinary bladder: a rare case of aggressively behaving primary well-differentiated neuroendocrine tumour with review of literature.
Topics: 3-Iodobenzylguanidine; Administration, Intravenous; Adult; Cell Differentiation; Diagnosis, Differential; Enzyme Inhibitors; Humans; Liver Neoplasms; Male; Neoplasm Metastasis; Neuroendocrine Tumors; Peritoneal Neoplasms; Treatment Outcome; Urinary Bladder | 2019 |
[Theranostics in 2020: Neuroendocrine tumors].
Topics: 3-Iodobenzylguanidine; Forecasting; Humans; Neuroendocrine Tumors; Theranostic Nanomedicine | 2020 |
The Current State of Radiopharmaceutical Therapy.
Topics: 3-Iodobenzylguanidine; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Radiopharmaceuticals | 2018 |
Sequelae and survivorship in patients treated with (131)I-MIBG therapy.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adult; Chromaffin Cells; Cohort Studies; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Neuroendocrine Tumors; Radiopharmaceuticals; Retrospective Studies | 2013 |
Resolution of Malignant Ascites and Stabilization of Metastases in a Patient With Small Bowel Neuroendocrine Tumor With 177Lu-DOTATATE Following Progression After 17 131I-MIBG Treatments and Chemotherapy.
Topics: 3-Iodobenzylguanidine; Adult; Antineoplastic Agents; Ascites; Bone Neoplasms; Disease Progression; Humans; Intestinal Neoplasms; Liver Neoplasms; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Peritoneal Neoplasms; Radiopharmaceuticals | 2015 |
Incidental Acinic Cell Carcinoma of the Parotid Gland Discordant on 123I-MIBG, 111In-Octreotide, and 18F-FDG PET/CT in a Patient With Neuroendocrine Tumor of the Cecum.
Topics: 3-Iodobenzylguanidine; Carcinoma, Acinar Cell; Cecal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Parotid Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Draft guidelines regarding appropriate use of (131)I-MIBG radiotherapy for neuroendocrine tumors : Guideline Drafting Committee for Radiotherapy with (131)I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine.
Topics: 3-Iodobenzylguanidine; Humans; Neuroendocrine Tumors; Radiopharmaceuticals; Radiotherapy | 2015 |
Dosimetric results in treatments of neuroblastoma and neuroendocrine tumors with (131)I-metaiodobenzylguanidine with implications for the activity to administer.
Topics: 3-Iodobenzylguanidine; Adolescent; Bone Marrow; Child; Child, Preschool; Dose-Response Relationship, Radiation; Female; Humans; Iodine Radioisotopes; Male; Neuroblastoma; Neuroendocrine Tumors; Radionuclide Imaging; Radiotherapy Dosage; Whole-Body Counting; Young Adult | 2015 |
Long-term outcomes of (131)Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiopharmaceuticals; Survival Analysis | 2015 |
Cardiac metastases of neuroendocrine tumors treated with 177Lu DOTATATE peptide receptor radionuclide therapy or 131I-MIBG therapy.
Topics: 3-Iodobenzylguanidine; Aged; Female; Heart Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiopharmaceuticals; Thymus Neoplasms | 2015 |
Orbital Metastases of Neuroendocrine Tumors Treated With 177Lu-DOTATATE PRRT or 131I-MIBG Therapies.
Topics: 3-Iodobenzylguanidine; Humans; Neuroendocrine Tumors; Octreotide; Orbital Neoplasms; Organometallic Compounds; Radiopharmaceuticals | 2016 |
[Draft guideline regarding appropriate use of 131I-MIBG radiotherapy for neuroendocrine tumors Drafting Committee for Guideline of Radiotherapy with 131I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine].
Topics: 3-Iodobenzylguanidine; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Nuclear Medicine; Practice Guidelines as Topic; Radiopharmaceuticals; Societies, Medical; Treatment Outcome | 2015 |
131I-MIBG Therapy in a Metastatic Small Bowel Neuroendocrine Tumor Patient Undergoing Hemodialysis.
Topics: 3-Iodobenzylguanidine; Aged; Female; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Radiopharmaceuticals; Renal Dialysis | 2017 |
[Guideline draft of appropriate use of 131I-MIBG for internal radiotherapy of neuroendocrine tumors].
Topics: 3-Iodobenzylguanidine; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Practice Guidelines as Topic | 2008 |
Increased uptake of (131)I-MIBG after intra-arterial application in liver metastases of a neuroendocrine tumor.
Topics: 3-Iodobenzylguanidine; Aged; Humans; Liver Neoplasms; Male; Neuroendocrine Tumors; Radionuclide Imaging; Radiopharmaceuticals | 2010 |
Efficacy of using a standard activity of (131)I-MIBG therapy in patients with disseminated neuroendocrine tumours.
Topics: 3-Iodobenzylguanidine; Biomarkers, Tumor; Disease Progression; Female; Hormones; Humans; Male; Middle Aged; Neuroendocrine Tumors; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed; Tumor Burden | 2010 |
Intraarterial 131I-MIBG therapy of neuroendocrine tumors with liver metastases.
Topics: 3-Iodobenzylguanidine; Aged; Female; Humans; Infusions, Intra-Arterial; Iodine Radioisotopes; Liver Neoplasms; Neoplasm Metastasis; Neuroendocrine Tumors | 2010 |
Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Cell Proliferation; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Ki-67 Antigen; Male; Middle Aged; Neuroendocrine Tumors; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, Emission-Computed | 2010 |
Efficient production of therapeutic doses of [131I]-metaiodobenzylguanidine for clinical use.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Radiopharmaceuticals | 2011 |
False positive uptake of metaiodobenzylguanidine in hepatocellular carcinoma.
Topics: 3-Iodobenzylguanidine; Aged; Carcinoma, Hepatocellular; Diagnosis, Differential; False Positive Reactions; Humans; Hypertension; Liver Neoplasms; Male; Neuroendocrine Tumors; Radionuclide Imaging; Radiopharmaceuticals | 2002 |
Meta-iodobenzylguanidine induces growth inhibition and apoptosis of neuroendocrine gastrointestinal tumor cells.
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Cell Cycle; Cell Division; Colorectal Neoplasms; DNA Primers; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Intracellular Membranes; L-Lactate Dehydrogenase; Membrane Potentials; Mitochondria; Neoplasm Proteins; Neuroendocrine Tumors; Norepinephrine Plasma Membrane Transport Proteins; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Symporters; Tumor Cells, Cultured | 2002 |
Monitoring the efficacy of iodine-131-MIBG therapy using fluorine-18-FDG-PET.
Topics: 3-Iodobenzylguanidine; Biological Transport; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Radiopharmaceuticals; Reproducibility of Results; Tissue Distribution; Tomography, Emission-Computed | 2003 |
123I-Metaiodobenzylguanidine uptake in the nape of the neck of children: likely visualization of brown adipose tissue.
Topics: 3-Iodobenzylguanidine; Adipose Tissue, Brown; Child; Child, Preschool; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Infant; Infant, Newborn; Male; Neck; Neuroendocrine Tumors; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies | 2003 |
Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adrenergic Uptake Inhibitors; Animals; Antineoplastic Agents; Blotting, Western; Chromogranin A; Chromogranins; Clomipramine; Humans; Immunoenzyme Techniques; Iodine Radioisotopes; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Nerve Tissue Proteins; Neuroendocrine Tumors; Neuropeptides; Pheochromocytoma; Reserpine; Selective Serotonin Reuptake Inhibitors; Tumor Cells, Cultured; Vesicular Biogenic Amine Transport Proteins | 2003 |
131I/123I-metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging.
Topics: 3-Iodobenzylguanidine; Europe; Humans; Iodine Radioisotopes; Neoplasms; Neuroendocrine Tumors; Nuclear Medicine; Patient Care Management; Practice Guidelines as Topic; Practice Patterns, Physicians'; Radiopharmaceuticals; Societies, Medical; Tomography, Emission-Computed | 2003 |
Importance of vesicle proteins in the diagnosis and treatment of neuroendocrine tumors.
Topics: 3-Iodobenzylguanidine; Adenocarcinoma; Adrenal Gland Neoplasms; Adrenergic Uptake Inhibitors; Biopsy; Carcinoid Tumor; Chromogranins; Clomipramine; Gastrointestinal Neoplasms; GTP-Binding Protein alpha Subunits, Gs; Humans; Iodine Radioisotopes; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Neuroblastoma; Neuroendocrine Tumors; Neuropeptides; Pancreatic Neoplasms; Pheochromocytoma; Radionuclide Imaging; Reserpine; Selective Serotonin Reuptake Inhibitors; Synaptic Vesicles; Tumor Cells, Cultured; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2004 |
A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidine.
Topics: 3-Iodobenzylguanidine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Caspases; Cell Cycle; Drug Synergism; G1 Phase; Gastrointestinal Neoplasms; Humans; Interferon-gamma; Neuroendocrine Tumors; Norepinephrine Plasma Membrane Transport Proteins; Receptors, Interferon; Resting Phase, Cell Cycle; Reverse Transcriptase Polymerase Chain Reaction; S Phase; Statistics, Nonparametric; Symporters; Tumor Cells, Cultured; Up-Regulation | 2004 |
Bilateral orbital metastases from a neuroendocrine tumor.
Topics: 3-Iodobenzylguanidine; Aged; Female; Humans; Liver Neoplasms; Neoplasms, Connective Tissue; Neuroendocrine Tumors; Octreotide; Orbital Neoplasms; Radionuclide Imaging; Tomography, X-Ray Computed | 2004 |
The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Cohort Studies; Female; Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Palliative Care; Radiopharmaceuticals; Thyroid Neoplasms; Treatment Outcome | 2004 |
Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Female; Humans; Longitudinal Studies; Male; Middle Aged; Multiple Endocrine Neoplasia; Neuroendocrine Tumors; Radiopharmaceuticals; Radiotherapy Dosage; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2005 |
Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG.
Topics: 3-Iodobenzylguanidine; Aged; Antineoplastic Agents; Carcinoid Tumor; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Radionuclide Imaging; Radiopharmaceuticals; Whole Body Imaging | 2005 |
Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Digestive System Neoplasms; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Reproducibility of Results; Sensitivity and Specificity; Somatostatin | 2006 |
Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
Topics: 3-Iodobenzylguanidine; Drug Therapy, Combination; Humans; Iodine Radioisotopes; Models, Biological; Neuroendocrine Tumors; Octreotide; Radiation Dosage; Radiopharmaceuticals; Yttrium Radioisotopes | 2006 |
Intertumoural variability in functional imaging within patients suffering from neuroendocrine tumours. An observational, cross-sectional study.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Somatostatin; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2005 |
Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".
Topics: 3-Iodobenzylguanidine; Animals; Clinical Trials as Topic; Dose-Response Relationship, Radiation; Humans; Iodine Radioisotopes; Lymphoma; Maximum Tolerated Dose; Neuroendocrine Tumors; Peptides; Radioimmunotherapy; Radiometry; Radiotherapy; Thyroid Neoplasms | 2007 |
Whole-body iodine-131 metaiodobenzylguanidine imaging for detection of bone metastases in patients with paraganglioma: comparison with bone scintigraphy.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Bone and Bones; Bone Neoplasms; Female; Humans; Iodine Radioisotopes; Neoplasm Metastasis; Neuroendocrine Tumors; Paraganglioma; Radionuclide Imaging; Radiopharmaceuticals; Whole Body Imaging | 2007 |
Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Female; Hematologic Diseases; Humans; Iodine Radioisotopes; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Radiopharmaceuticals; Survival Analysis | 2008 |
Utility of thallium-201 and iodine-123 metaiodobenzylguanidine in the scintigraphic detection of neuroendocrine neoplasia.
Topics: 3-Iodobenzylguanidine; Female; Humans; Iodine Radioisotopes; Iodobenzenes; Male; Neuroblastoma; Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma; Radionuclide Imaging; Thallium Radioisotopes; Thyroid Neoplasms | 1993 |
Imaging secondary neuroendocrine tumours of the liver: comparison of I123 metaiodobenzylguanidine (MIBG) and In111-labelled octreotide (Octreoscan).
Topics: 3-Iodobenzylguanidine; Bone Neoplasms; Humans; Indium Radioisotopes; Iodine Radioisotopes; Iodobenzenes; Liver Neoplasms; Neuroendocrine Tumors; Octreotide; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon | 1996 |
Meta-[131I]iodobenzylguanidine in the scintigraphic evaluation of neural crest tumors.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adult; Carcinoid Tumor; Carcinoma, Medullary; Child; False Negative Reactions; False Positive Reactions; Follow-Up Studies; Heart; Humans; Hyperaldosteronism; Injections, Intravenous; Insulinoma; Iodine Radioisotopes; Iodobenzenes; Middle Aged; Myocardium; Neuroblastoma; Neuroendocrine Tumors; Pancreatic Neoplasms; Paraganglioma; Pheochromocytoma; Radionuclide Imaging; Radiopharmaceuticals; Salivary Glands; Sensitivity and Specificity; Thyroid Neoplasms | 1995 |
MIBG and radiolabeled octreotide in neuroendocrine tumors.
Topics: 3-Iodobenzylguanidine; Autoimmune Diseases; Cell Membrane; Cytoplasmic Granules; Forecasting; Granuloma; Humans; Indium Radioisotopes; Iodine Radioisotopes; Iodobenzenes; Neuroendocrine Tumors; Octreotide; Palliative Care; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Cell Surface; Receptors, Somatostatin; Somatostatin; Treatment Outcome | 1995 |
Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Carcinoid Tumor; Carcinoma, Medullary; Carcinoma, Merkel Cell; Female; Humans; Indium Radioisotopes; Iodine Radioisotopes; Iodobenzenes; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organotechnetium Compounds; Pheochromocytoma; Pituitary Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Skin Neoplasms; Sugar Acids; Technetium Compounds; Thyroid Neoplasms | 1995 |
Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
Topics: 3-Iodobenzylguanidine; Administration, Inhalation; Autoimmune Diseases; Biogenic Amines; Cardiomyopathies; Combined Modality Therapy; Heart; Humans; Indium Radioisotopes; Injections, Intravenous; Iodine Radioisotopes; Iodobenzenes; Lung; Neuroendocrine Tumors; Octreotide; Peptides; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Sympathetic Nervous System; Technetium; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1995 |
Brain uptake of iodine-131 metaiodobenzylguanidine following therapy of malignant pheochromocytoma.
Topics: 3-Iodobenzylguanidine; Adolescent; Adrenal Gland Neoplasms; Adrenergic Agonists; Adrenergic alpha-Agonists; Adult; Age Factors; Aged; Blood-Brain Barrier; Body Mass Index; Brain; Cerebellum; Epinephrine; Evaluation Studies as Topic; Female; Humans; Male; Metanephrine; Middle Aged; Neuroendocrine Tumors; Norepinephrine; Pheochromocytoma; Radiopharmaceuticals; Radiotherapy Dosage; Retrospective Studies; Sex Factors; Single-Blind Method | 1998 |
Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
Topics: 3-Iodobenzylguanidine; Adolescent; Adult; Child; Child, Preschool; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Radionuclide Imaging; Radiopharmaceuticals | 2000 |
Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Topics: 3-Iodobenzylguanidine; Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Carcinoid Tumor; Child; Female; Humans; Indium Radioisotopes; Insulinoma; Iodine Radioisotopes; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Paraganglioma; Pheochromocytoma; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Somatostatin; Thyroid Neoplasms; Tomography, X-Ray Computed | 2001 |
[Informed consent in the radioisotopic treatment of neuroendocrine tumors].
Topics: 3-Iodobenzylguanidine; Forms and Records Control; Humans; Informed Consent; Mental Competency; Neuroendocrine Tumors; Radiopharmaceuticals | 2001 |
Functional imaging of malignant paragangliomas and carcinoid tumours.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Carcinoid Tumor; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Paraganglioma; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2001 |
The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Child, Preschool; Endocrine Gland Neoplasms; Female; Gamma Cameras; Humans; Image Processing, Computer-Assisted; Iodine Radioisotopes; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Selenium Radioisotopes; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2001 |
Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Medullary; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma; Radiopharmaceuticals; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Thyroid Neoplasms; Treatment Outcome | 2001 |
Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, Radiation; Drug Administration Schedule; Female; Humans; Hypothyroidism; Iodine Radioisotopes; Male; Middle Aged; Neoplasms, Radiation-Induced; Neuroendocrine Tumors; Potassium Iodide; Premedication; Radiopharmaceuticals; Thyroid Gland; Thyroid Neoplasms; Thyrotropin | 2002 |